Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

RareStone In-Licenses China Rights to Obesity Therapy in $75 Million Deal

publication date: Dec 6, 2021

RareStone, a Shanghai-Boston rare disease company, in-licensed greater China rights to a therapy for genetic obesity from Rhythm Pharma in a $75 million agreement. Rhythm’s IMCIVREE was approved in the US last year to treat severe, early-onset obesity and hyperphagia caused by the acquired and genetic melanocortin-4 receptor (MC4R) pathway. Founded in 2019 by Eight Roads, F-Prime Capital and Vivo Capital, RareStone completed an $80 million Series A one year ago to develop rare disease therapies in China. It was originally known as Citrine Medicine. More details....

Stock Symbol: (NSDQ: RYTM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China